The company has not filed an annual or quarterly report since its Q1 FY2020 10-Q, filed May 11, 2020. Its latest SEC filing is a SC 13G/A from Feb 12, 2021.
10-Q for Q1 FY2020, filed May 11, 2020
The sections below describe the company as of the FY2019 annual report.
Sells ELZONRIS, a targeted cancer therapy, to specialty distributors and an international distributor for hospitals treating patients with BPDCN; develops additional cancer drug candidates.
10-K for FY2019, filed Mar 16, 2020
Stemline sells ELZONRIS to a U.S. customer that resells it to specialty distributors, which supply specialty hospitals. An international customer distributes it directly to hospitals in certain countries participating in the early access program.
10-K for FY2019, filed Mar 16, 2020The Company sells ELZONRIS in the U.S. to one customer and one customer internationally through a title distribution channel. The U.S.…View ↗
10-Q for Q1 FY2020, filed May 11, 2020
−$21.3MView ↗
8-K, filed Jun 10, 2020
On June 10, 2020, Stemline (i) notified the Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Merger and (ii) requested that…View ↗
8-K, filed May 4, 2020
Pursuant to the terms and subject to the conditions of the Merger Agreement, Purchaser will commence a tender offer (the “Offer”) no later…View ↗
From clinical development to commercial sales
The earlier report described Stemline as a clinical-stage company developing a targeted therapy and other candidates, with commercialization still potential. The latest report describes an FDA-approved, commercially available product and a commercial-stage company.
10-K for FY2016, filed Mar 16, 2017 10-K for FY2019, filed Mar 16, 2020We are a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology…View ↗
Competes with Verastem, OncoMed Pharmaceuticals, Sumitomo Dainippon Pharma, Bionomics, Stemcentrx, Astellas Pharma US, Boehringer Ingelheim, Geron, GlaxoSmithKline, Ignyta, Macrogenics, Micromet, Pfizer, Roche Holding, Sanofi U.S., AbbVie, Amgen, Celgene, Cellectis, and Cyclacel Pharmaceuticals
10-K for FY2019, filed Mar 16, 2020There are several biopharmaceutical companies whose primary focus appears to be developing therapies against CSCs, including Verastem…View ↗
Loading...
